falsefalse

Evolving Treatment in Newly Diagnosed Multiple Myeloma Patients - Episode 7

Overview of PERSEUS, IsKia, and GMMG-HD7

Douglas Sborov, MD, discusses a brief overview of key clinical trials, including PERSEUS, IsKia, and GMMG-HD7, highlighting their implications for the treatment of patients with NDMM.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients
    EP. 2: Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials
    EP. 3: Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy
    EP. 4: Optimizing Regimens and Managing Adverse Events in TIE NDMM
    EP. 5: Looking Ahead and Key Takeaways
    EP. 6: Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients
    Now Viewing
    EP. 7: Overview of PERSEUS, IsKia, and GMMG-HD7
    EP. 8: Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM
    1. Please provide a brief overview of the following trials:
    • PERSEUS
    • IsKia
    • GMMG-HD7

    Related Content:

    Evolving Treatment in Newly Diagnosed Multiple Myeloma Patients
    Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM
    Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients
    Looking Ahead and Key Takeaways
    x